Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis

CONCLUSION: Thirty-day mortality was significantly lower in patients with COVID-19 pneumonia treated with baricitinib plus dexamethasone versus dexamethasone monotherapy. No difference was observed in progression to invasive mechanical ventilation and hospital acquired infections.PMID:34294593 | DOI:10.1016/j.jmii.2021.05.009

Source: Journal of Microbiology, Immunology, and Infection - July 23, 2021 Category: Microbiology Authors: Eduardo P érez-Alba Laura Nuzzolo-Shihadeh Gloria Mayela Aguirre-Garc ía Jaime Espinosa-Mora Juan Diego Lecona-Garcia Romulo Omar Flores-P érez Marisela Mendoza-Garza Adri án Camacho-Ortiz Source Type: research